| Dr Aaron Lang, MD | |
|
1723 Broadway St, Suite 315, Cape Girardeau, MO 63701-4505 | |
| (573) 332-0226 | |
| (573) 332-0344 |
| Full Name | Dr Aaron Lang |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 1723 Broadway St, Cape Girardeau, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043281413 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 2004012760 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Aaron Lang, MD 1723 Broadway St, Suite 315, Cape Girardeau, MO 63701-4505 Ph: (573) 332-0226 | Dr Aaron Lang, MD 1723 Broadway St, Suite 315, Cape Girardeau, MO 63701-4505 Ph: (573) 332-0226 |
News Archive
FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.
The Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC) has provided funding to support joint research between the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust to investigate why some cases of Clostridium difficile infection (CDI) are more difficult to treat than others and also why some cases result in more incidences of relapses.
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
› Verified 1 days ago
Kenneth W Retter, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 211 Saint Francis Dr Ste 15, Cape Girardeau, MO 63703 Phone: 573-331-3333 | |
Philip W Taylor, M.D., FACP Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 3250 Gordonville Rd, Ste 301, Cape Girardeau, MO 63703 Phone: 573-334-9641 Fax: 573-331-3120 | |
Tibebe Haile, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1701 Lacey St, Cape Girardeau, MO 63701 Phone: 573-331-6431 Fax: 573-986-5984 | |
Dr. Tiffany Renae Samples, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 211 Saint Francis Dr, Cape Girardeau, MO 63703 Phone: 573-331-5770 Fax: 573-331-3974 | |
Narjes F Alamri, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3250 Gordonville Rd Ste 301, Cape Girardeau, MO 63703 Phone: 573-334-9641 Fax: 573-331-4130 | |
Rebecca L Smith, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 211 Saint Francis Dr, Suite 15, Cape Girardeau, MO 63703 Phone: 573-331-3333 Fax: 573-331-3334 |